Safety and Efficacy of Roux-en-Y Gastric Bypass to Treat Type 2 Diabetes Mellitus in Non-severely Obese Patients

Simple item page
dc.contributor.authorBoza, Camilo
dc.contributor.authorMunoz, Rodrigo
dc.contributor.authorSalinas, Jose
dc.contributor.authorGamboa, Cristian
dc.contributor.authorKlaassen, Julieta
dc.contributor.authorEscalona, Alex
dc.contributor.authorPerez, Gustavo
dc.contributor.authorIbanez, Luis
dc.contributor.authorGuzman, Sergio
dc.date.accessioned2025-01-21T00:00:56Z
dc.date.available2025-01-21T00:00:56Z
dc.date.issued2011
dc.description.abstractThe efficacy of Roux-en-Y gastric bypass (RYGB) to control type 2 diabetes mellitus (T2DM) has been demonstrated in morbidly obese patients. Surgical procedures primarily focused on T2DM control in patients with body mass index (BMI) < 35 kg/m(2) have shown to effectively induce remission of T2DM. However, only few reports have evaluated the safety and efficacy of RYGB in this group of patients. The aim of this study is to assess the safety and efficacy of RYGB in TD2M patients with BMI < 35 kg/m(2). All T2DM patients with BMI < 35 kg/m(2) and at least 12 months of follow-up who underwent laparoscopic RYGB were included. Safety of the procedure was evaluated according to mortality, need of reoperation/conversion, and complication rates. Metabolic parameters were evaluated at baseline and 6, 12, and 24 months after surgery. Thirty patients were included. Seventeen (56.6%) were women. Age, BMI, and duration of diabetes were 48 +/- 9 years, 33.7 +/- 1.2 kg/m(2), 4 +/- 2.9 years, respectively. No mortality was observed. No conversion/reoperation was needed. Average length of stay was 3.2 +/- 0.9 days. Early and late postoperative complications were observed in five (16.6%) and five (16.6%) patients, respectively. Twelve months after surgery, remission was observed in 25 of 30 patients (83.3%). After 2 years, remission was achieved in 13 of 20 patients (65%), and hemoglobin A1c decreased from 8.1 +/- 1.8% to 5.9 +/- 1.1% and homeostasis model assessment of insulin resistance from 5.7 +/- 3.2 to 1.9 +/- 0.8 after 12 months. RYGB is a safe and effective procedure to induce T2DM remission in otherwise not eligible patients for bariatric surgery. Evidence from prospective studies is needed to validate this approach.
dc.fuente.origenWOS
dc.identifier.doi10.1007/s11695-011-0463-5
dc.identifier.eissn1708-0428
dc.identifier.issn0960-8923
dc.identifier.urihttps://doi.org/10.1007/s11695-011-0463-5
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/95364
dc.identifier.wosidWOS:000294015200003
dc.issue.numero9
dc.language.isoen
dc.pagina.final1336
dc.pagina.inicio1330
dc.revistaObesity surgery
dc.rightsacceso restringido
dc.subjectType 2 diabetes mellitus
dc.subjectGastric bypass surgery
dc.subjectObesity
dc.subjectMetabolic surgery
dc.subjectNon-severe obesity
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleSafety and Efficacy of Roux-en-Y Gastric Bypass to Treat Type 2 Diabetes Mellitus in Non-severely Obese Patients
dc.typeartículo
dc.volumen21
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas